Acute Coronary Syndrome: Secondary Prevention | Treatment Algorithms: Claims Data Analysis | US | 2025

Acute coronary syndrome (ACS)—a subtype of coronary artery disease—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. This report focuses on the posthospital, secondary prevention of ACS, aimed at preventing recurrent CV events and adverse cardiac remodeling and prolonging the patient’s survival. The current ACS secondary prevention market is dominated by generic therapies. Branded options include PCSK9 inhibitors (Amgen’s Repatha [evolocumab], Sanofi / Regeneron’s Praluent [alirocumab]); antiplatelets (AstraZeneca’s Brilinta [ticagrelor]); ACL inhibitors (Esperion’s Nexletol / Nexlizet [bempedoic acid]); anti-inflammatory agents (Agepha Pharma’s Lodoco [colchicine]); and prescription omega-3 fatty acids (Amarin’s Vascepa [icosapent ethyl]. In this report, we analyze the secondary prevention of ACS in the United States and provide insight into the factors driving the current treatment of newly diagnosed and recently treated patients.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed post-ACS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed post-ACS patients?
• How have Repatha, Praluent, and Nexletol been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of post-ACS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of post-ACS patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Key drugs covered

Evolocumab, alirocumab, bempedoic acid, icosapent ethyl, ticagrelor

Key analyses:

• Brand / therapy usage across longitudinal patient sample
• Newly diagnosed patient analysis
• Treatment initiation and progression
• Line of therapy analysis
• Combination therapy analysis
• Source of business for recently treated patients
• Persistency and compliance analysis
• Product-level patient flow charts

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.Dashboard featuring interactive visuals, easy navigation, and expanded analyses